In vitro pharmacodynamics of human simulated exposures of ceftaroline and daptomycin against MRSA, hVISA, and VISA with and without prior vancomycin exposure

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 2, 2014, Pages 672-677

  Bhalodi, Amira A ^a   Hagihara, Mao ^a,b   Nicolau, David P ^a   Kuti, Joseph L ^a  

^a HARTFORD HOSPITAL   (United States)

^b AICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAROLINE; DAPTOMYCIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; COLONY FORMING UNIT; DRUG EXPOSURE; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; COLONY COUNT, MICROBIAL; DAPTOMYCIN; DRUG COMBINATIONS; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MODELS, STATISTICAL; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 84893489884     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01516-13     Document Type: Article

References (35)

1. Corey GR. 2009. Staphylococcus aureus bloodstream infections: definitions and treatment. Clin. Infect. Dis. 48(Suppl):S254-S259. http://dx.doi.org/10. 1086/598186.
2. Han JH, Mascitti KB, Edelstein PH, Bilker WB, Lautenbach E. 2012. Effect of reduced vancomycin susceptibility on clinical and economic outcomes in Staphylococcus aureus bacteremia. Antimicrob. Agents Chemother. 56:5164-5170. http://dx.doi.org/10.1128/AAC.00757-12.
3. Kullar R, Davis SL, Levine DP, Rybak MJ. 2011. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. Clin. Infect. Dis. 52:975-981. http://dx.doi.org/10.1093/cid/cir124.
4. Moise PA, Sakoulas G, Forrest A, Schentag JJ. 2007. Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob. Agents Chemother. 51:2582-2586. http://dx.doi.org/10.1128/AAC.00939-06.
5. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, Rybak M, Talan DA, Chambers HF. 2011. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin. Infect. Dis. 52: e18-e55. http://dx.doi.org/10.1093/ cid/ciq146.
6. Sader HS, Fritsche TR, Kaniga K, Ge Y, Jones RN. 2005. Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains. Antimicrob. Agents Chemother. 49:3501-3512. http://dx.doi.org/10.1128/AAC.49.8.3501-3512.2005.
7. Cha R, Brown WJ, Rybak MJ. 2003. Bactericidal activities of daptomycin, quinupristin-dalfopristin, and linezolid against vancomycin-resistant Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob. Agents Chemother. 47:3960-3963. http://dx.doi.org/10.1128/AAC.47.12.3960-3963.2003.
8. Sakoulas G, Alder J, Thauvin-Eliopoulos C, Moellering RC, Eliopoulos GM. 2006. Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob. Agents Chemother. 50:1581-1585. http://dx.doi.org/10.1128/AAC.50.4.1581-1585.2006.
9. Cui L, Tominaga E, Neoh HM, Hiramatsu K. 2006. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 50:1079-1082. http://dx.doi.org/10.1128/AAC.50.3.1079-1082.2006.
10. Saravolatz L, Pawlak J, Johnson L. 2010. In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycinintermediate, vancomycin-resistant, and daptomycin-non-susceptible Staphylococcus aureus isolates. Antimicrob. Agents Chemother. 54:3027-3030. http://dx.doi.org/10.1128/ AAC.01516-09.
11. Jacqueline C, Caillon J, Le Mabecque V, Miegeville AF, Hamel A, Bugnon D, Ge JY, Potel G. 2007. In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model. Antimicrob. Agents Chemother. 51:3397-3400. http://dx.doi.org/10.1128/AAC.01242-06.
12. Ho TT, Cadena J, Childs LM, Gonzalez-Velez M, Lewis JS. 2012. Methicillin-resistant Staphylococcus aureus bacteraemia and endocarditis treated with ceftaroline salvage therapy. J. Antimicrob. Chemother. 67: 1267-1270. http://dx.doi.org/10.1093/jac/dks006.
13. Clinical and Laboratory Standards Institute. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard, 9th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
14. Benvenuto M, Benziger DP, Yankelev S, Vigliani G. 2006. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob. Agents Chemother. 50:3245-3249. http://dx.doi.org/10.1128/AAC.00247-06.
15. Forest Laboratories, Inc. 2010. Teflaro package insert. Forest Laboratories, Inc., St. Louis, MO.
16. Albrecht LM, Rybak MJ, Warbasse LH, Edwards DJ. 1991. Vancomycin protein binding in patients with infections caused by Staphylococcus aureus. DICP 25:713-715.
17. Kuti JL, Kiffer CR, Mendes CM, Nicolau DP. 2008. Pharmacodynamic comparison of linezolid, teicoplanin and vancomycin against clinical isolates of Staphylococcus aureus and coagulase-negative staphylococci collected from hospitals in Brazil. Clin. Microbiol. Infect. 14:116-123. http://dx.doi.org/10. 1111/j.1469-0691.2007.01885.x.
18. Keel RA, Crandon JL, Nicolau DP. 2011. Efficacy of human simulated exposures of ceftaroline administered at 600 milligrams every 12 hours against phenotypically diverse Staphylococcus aureus isolates. Antimicrob. Agents Chemother. 55:4028-4032. http://dx.doi.org/10.1128/AAC.00372-11.
19. Hagihara M, Wiskirchen DE, Kuti JL, Nicolau DP. 2012. In vitro pharmacodynamics of vancomycin and cefazolin alone and in combination against methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 56:202-207. http://dx.doi.org/10.1128/AAC.05473-11.
20. Lamp KC, Rybak MJ, Bailey EM, Kaatz GW. 1992. In vitro pharmacodynamic effects of concentration, pH, and growth phase on serum bactericidal activities of daptomycin and vancomycin. Antimicrob. Agents Chemother. 36:2709-2714. http://dx.doi.org/10.1128/AAC.36.12.2709.
21. Dandekar PK, Tessier PR, Williams P, Nightingale CH, Nicolau DP. 2003. Pharmacodynamic profile of daptomycin against Enterococcus species and methicillin-resistant Staphylococcus aureus in a murine thigh infection model. J. Antimicrob. Chemother. 52:405-411. http://dx.doi.org/10.1093/jac/dkg337.
22. Akins RL, Rybak MJ. 2001. Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob. Agents Chemother. 45:454-459. http://dx.doi.org/10.1128/AAC.45.2.454-459.2001.
23. LaPlante KL, Rybak MJ. 2004. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob. Agents Chemother. 48:4665-4672. http://dx.doi.org/10.1128/AAC.48.12. 4665-4672.2004.
24. Steed M, Vidaillac C, Rybak MJ. 2011. Evaluation of ceftaroline activity versus daptomycin (DAP) against DAP-nonsusceptible methicillinresistant Staphylococcus aureus strains in an in vitro pharmacokinetic/ pharmacodynamic model. Antimicrob. Agents Chemother. 55:3522-3526. http://dx.doi.org/10.1128/ AAC.00347-11.
25. Lodise TP, Jr, McKinnon PS, Rybak M. 2003. Prediction model to identify patients with Staphylococcus aureus bacteremia at risk for methicillin resistance. Infect. Control Hosp. Epidemiol. 24:655-661. http://dx.doi.org/10. 1086/502269.
26. Levine DP, Fromm BS, Reddy BR. 1991. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann. Intern. Med. 115:674-680. http://dx.doi.org/10.7326/0003- 4819-115-9-674.
27. Gentry CA, Rodvold KA, Novak RM, Hershow RC, Naderer OJ. 1997. Retrospective evaluation of therapies for Staphylococcus aureus endocarditis. Pharmacotherapy 17:990-997.
28. Larsson AJ, Walker KJ, Raddatz JK, Rotschafer JC. 1996. The concentration-independent effect of monoexponential and biexponential decay in vancomycin concentrations on the killing of Staphylococcus aureus under aerobic and anaerobic conditions. J. Antimicrob. Chemother. 38:589-597. http://dx.doi.org/10.1093/jac/38.4.589.
29. Bowker KE, Noel AR, MacGowan AP. 2009. Comparative antibacterial effects of daptomycin, vancomycin and teicoplanin studied in an in vitro pharmacokinetic model of infection. J. Antimicrob. Chemother. 64: 1044-1051. http://dx.doi.org/10.1093/jac/dkp289.
30. Andes D, Craig WA. 2006. Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target. Antimicrob. Agents Chemother. 50:1376-1383. http://dx.doi.org/10.1128/AAC.50.4.1376-1383.2006.
31. Vidaillac C, Leonard SN, Rybak MJ. 2009. In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus and heterogeneous vancomycin-intermediate S. aureus in a hollow fiber model. Antimicrob. Agents Chemother. 53:4712-4717. http://dx.doi.org/10.1128/AAC.00636-09.
32. Cha R, Rybak MJ. 2004. Influence of protein binding under controlled conditions on the bactericidal activity of daptomycin in an in vitro pharmacodynamic model. J. Antimicrob. Chemother. 54:259-262. http://dx.doi.org/10.1093/jac/dkh259.
33. Rose WE, Leonard SN, Sakoulas G, Kaatz GW, Zervos MJ, Sheth A, Carpenter CF, Rybak MJ. 2008. Daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob. Agents Chemother. 52:831-836. http://dx.doi.org/10.1128/AAC.00869-07.
34. Friedman L, Alder JD, Silverman JA. 2006. Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus. Antimicrob. Agents Chemother. 50:2137-2145. http://dx.doi.org/10.1128/AAC.00039-06.
35. Moise PA, Amodio-Groton M, Rashid M, Lamp KC, Hoffman-Roberts HL, Sakoulas G, Yoon MJ, Schweitzer S, Rastogi A. 2013. Multicenter evaluation of the clinical outcomes of daptomycin with and without concomitant beta-lactams in patients with Staphylococcus aureus bacteremia and mild to moderate renal impairment. Antimicrob. Agents Chemother. 57:1192-1200. http://dx.doi.org/10. 1128/AAC.02192-12.